AirXpanders touts study results

AirXpanders (ASX:AXP) said that a retrospective clinical study has concluded that the use of its AeroForm tissue expanders may be associated with reduced infection rates, less medical treatment and lower costs for patients and health systems. The Palo Alto-based company makes the AeroForm tissue expander for post-mastectomy breast reconstruction. The device is designed to expand and stretch the skin and underlying muscle prior to a permanent breast implant using small amounts of CO2 up to three times a day. Get the full story on our sister site, Medical Design & Outsourcing.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Featured Hospital Care Implants News Well Oncology Surgical Women's Health AirXpanders Johns Hopkins University Source Type: news